FridayMar 04, 2022 2:55 pm

ZJ Events Presents Alternative Products Expo to Discuss the Potential of the Alternative Products Ecosystem

Vendors, businesses, industries, CBD & alternative product vendors, researchers, and professionals are invited to attend the Alternative Products Expo at Fort Lauderdale on March 11-13th, 2022. Organized by ZJ Events, the event group is committed to bringing the industry’s best alternative products traders, vendors, and enthusiasts under one platform, while offering a fun and enriching experience. Alternative Products Expo is evolving to include a wide gamut of products featuring novel products and services that are disrupting traditional markets. Alternative Products Expo strives to bring the best industry products to the consumers while creating networking opportunities for traders and vendors attending…

Continue Reading

FridayMar 04, 2022 9:15 am

Studies Advance Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology for Significantly Improving Pharmaceutical Drugs

Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from…

Continue Reading

WednesdayMar 02, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022  Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value  In 2020, the global health and wellness market reached $4.436 trillion and is expected to grow at a CAGR of 5.5% from 2021 to 2030, resulting in an estimated value of $7.7 trillion by the end of the forecasted period (https://cnw.fm/hbx1E). The primary…

Continue Reading

TuesdayMar 01, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Now Controls All Aspects of its Michigan Operations Following PharmaCo’s Acquisition

RWB has received all regulatory approvals and closed its acquisition of PharmaCo, a Michigan-based marijuana company This acquisition opens RWB to over 22 properties, including dispensaries and cultivation sites, giving it complete control of all its operations, from cultivating the product to selling it It marks a key milestone for the company and its shareholders as it continues to execute key components of its growth strategy For the 2022 calendar year, the company looks to extend its branded product lines, update its dispensaries, create supply chain efficiencies, and grow revenue and profitability Red White & Bloom Brands (CSE: RWB) (OTCQX:…

Continue Reading

MondayFeb 28, 2022 9:15 am

As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation

Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products…

Continue Reading

FridayFeb 25, 2022 9:30 am

Flora Growth Corp. (NASDAQ: FLGC) Reaches Agreement with Israeli Product Distributor Artos Ltd. for Cannabis Sales

Flora Growth is a cannabis cultivator and distributor with a large cultivation site in central Colombia’s favorable growing climate Flora Growth recently announced an agreement with Israeli product distribution company Artos Ltd. to sell Flora’s high-THC cannabis flower to Israelis Colombia legalized the international export of cannabis flower last year for use in health and wellness industries Israelis comprise a large base of medical marijuana users and cannabis-based business enterprises  Colombia and Israel began strengthening ties last year for promoting entrepreneurial innovation, and the agreement between Flora Growth and Artos builds on those state efforts Cannabis cultivator and brand builder…

Continue Reading

ThursdayFeb 24, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Strengthening Expansion with Licensing and Vertical Integration Strategy

Cannabis and hemp multi-state operator Red White & Bloom Brands has established itself in fast-growing plant derivative markets from Michigan to Florida and California Michigan’s new legal adult-use market is proving fertile ground for development, and the company has leased manufacturing facilities and obtained full licensing in the state Thanks to the Michigan developments, Red White & Bloom is also expanding distribution of its Platinum Vape gummies and chocolates beyond California, where they have been popular The company’s brands are expected to expand in Michigan from distribution to 250-plus dispensaries to more than 400 dispensaries  Cannabis and CBD product brand…

Continue Reading

WednesdayFeb 23, 2022 10:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022

Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022 Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4.  Additionally, in what marks another critical milestone, the…

Continue Reading

FridayFeb 18, 2022 9:30 am

Flora Growth Corp. (NASDAQ: FLGC) Focused On Opportunities in the CBD Industry to Scale Operations

Luis Merchan, Flora Growth’s President and CEO, appeared on a webinar on February 11, 2022, highlighting the opportunities and challenges affecting the CBD industry in key markets He has reiterated the company’s commitment to leveraging the industry’s opportunities for the growth of its operations, expansion of its market reach, and value creation for its shareholders The CBD industry is projected to be valued at $20 billion by 2025, and Flora Growth plans to capitalize on this growth In 2020, CBD sales in the United States reached $4.6 billion. It is projected that by 2024, this industry will be valued at…

Continue Reading

WednesdayFeb 16, 2022 11:22 am

Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022

Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations  The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://cnw.fm/SOjPD).  During the animal study, it…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000